TriangleTepotinib + Ivonescimab (NCT07619339)
Tepotinib + Ivonescimab trial for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NCT07619339). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with non-small cell lung cancer that has a MET exon 14 skipping change.
The idea: combine tepotinib, a daily pill that targets MET, with ivonescimab, an antibody given by vein every three weeks. The study tests up to two doses of tepotinib to find the best one with few or mild side effects.
This phase 1 study plans 16 patients. At Memorial Sloan Kettering Cancer Center in New York, Paul Paik leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.